You are here

  • Home
  • Archive
  • Volume 7, Issue 2
  • Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

Article metrics

Article menu

Download PDFPDF

XML
Rheumatoid arthritis
Original research
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

 

Online download statistics by month:

Online download statistics by month: April 2021 to March 2024

AbstractFullPdf
Apr 202118017768
May 202134133371
Jun 2021767125
Jul 2021686221
Aug 2021646440
Sep 2021908822
Oct 2021848333
Nov 2021535325
Dec 2021686821
Jan 2022454314
Feb 2022454313
Mar 2022555512
Apr 2022918710
May 2022717022
Jun 2022606020
Jul 2022454424
Aug 2022616218
Sep 2022515011
Oct 2022737130
Nov 2022474617
Dec 2022514919
Jan 2023464520
Feb 2023585819
Mar 2023303014
Apr 2023373514
May 2023403525
Jun 2023343411
Jul 2023393617
Aug 2023535226
Sep 2023515020
Oct 202326247
Nov 2023524517
Dec 2023464616
Jan 2024534319
Feb 2024302616
Mar 2024494828
Total23632286805